An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants with Relapsing Multiple Sclerosis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503289-22-00

Acronym

J3K-MC-KIAB

Enrollment

Registered

2024-05-13

Start date

2024-07-05

Completion date

2025-12-15

Last updated

2026-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsing Multiple Sclerosis

Brief summary

Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions Cumulative number will be measured by magnetic resonance imaging (MRI) scans

Interventions

DRUG0.9% sodium chloride

DRUGGADOTERIC ACID

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions Cumulative number will be measured by magnetic resonance imaging (MRI) scans	—

Countries

France, Germany, Italy, Latvia, Lithuania, Poland, Slovakia

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026